Autosomal recessive limb-girdle muscular dystrophy, type 28
aw-toh-SOH-muhl ree-SEH-siv lim-GUR-dul MUS-kyoo-lur DIS-troh-fee, type 28
Also known as: LGMD2G, Limb-girdle muscular dystrophy 2G
At a Glance
What is Autosomal recessive limb-girdle muscular dystrophy, type 28?
Autosomal recessive limb-girdle muscular dystrophy, type 28 is a genetic disorder that primarily affects the muscles around the hips and shoulders. It is caused by mutations in specific genes that are inherited in an autosomal recessive pattern, meaning both parents must carry the mutated gene. Over time, individuals with this condition experience progressive muscle weakness and wasting, which can lead to difficulties in walking, climbing stairs, and lifting objects. Early symptoms often include muscle cramps and fatigue, while later stages may involve severe mobility issues and respiratory complications. Early diagnosis is critical to manage symptoms effectively and slow disease progression. The condition can have a significant impact on family life, as affected individuals may require assistance with daily activities and adaptations to their living environment. Prognosis varies, but many individuals maintain some level of independence with appropriate interventions. Daily life for those affected often involves physical therapy, assistive devices, and regular medical check-ups to monitor disease progression. The condition does not typically affect cognitive function, allowing individuals to engage in social and educational activities. However, the physical limitations can be emotionally challenging, requiring psychological support. Family members may also need genetic counseling to understand the inheritance pattern and risks for future generations.
Medical Definition
Autosomal recessive limb-girdle muscular dystrophy, type 28 is characterized by progressive weakness and wasting of the proximal limb muscles due to mutations in the SGCG gene. Pathologically, it involves the degeneration and regeneration of muscle fibers, with histological findings showing variation in fiber size, increased connective tissue, and fatty infiltration. It is classified under sarcoglycanopathies, a subgroup of limb-girdle muscular dystrophies. Epidemiologically, it is considered a rare disease with a low prevalence worldwide. The disease course is variable, with some individuals experiencing rapid progression while others have a more gradual decline. Management focuses on symptomatic treatment and supportive care to improve quality of life and maintain mobility as long as possible.
Autosomal recessive limb-girdle muscular dystrophy, type 28 Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Muscle weakness primarily affects the proximal muscles around the hips and shoulders. This weakness is due to the degeneration of muscle fibers caused by mutations affecting muscle protein function. Over time, the weakness progresses, leading to increased difficulty in performing daily activities. Patients may require physical therapy and assistive devices to maintain mobility and independence.
Patients often experience difficulty walking due to weakened hip and thigh muscles. This is caused by the progressive loss of muscle tissue and strength. As the condition advances, walking becomes increasingly challenging, often necessitating the use of mobility aids. Regular physiotherapy can help improve gait and balance, reducing the risk of falls.
Fatigue manifests as a persistent feeling of tiredness and lack of energy. It results from the increased effort required to perform tasks due to muscle weakness. Over time, fatigue can worsen, impacting the patient's ability to engage in daily activities and reducing their quality of life. Management includes energy conservation techniques and tailored exercise programs.
Common
Muscle atrophy is characterized by a noticeable decrease in muscle mass and strength. This occurs as muscle fibers deteriorate and are replaced by fatty or fibrous tissue. The atrophy progresses gradually, leading to further functional impairment. Physical therapy and nutritional support can help slow the progression of muscle wasting.
Joint contractures involve the stiffening and shortening of muscles around the joints, limiting movement. They are caused by prolonged muscle weakness and imbalance, leading to abnormal joint positioning. Without intervention, contractures can become permanent, severely restricting mobility. Stretching exercises and orthotic devices are commonly used to manage this symptom.
Back pain is a frequent complaint due to compensatory postures and muscle imbalances. It arises from the strain on muscles and ligaments as they attempt to stabilize weakened areas. Over time, chronic pain can develop, affecting daily activities and sleep quality. Pain management strategies include physical therapy, medication, and ergonomic adjustments.
Less Common
Respiratory issues may develop as the disease progresses, affecting the muscles involved in breathing. This is due to the weakening of the diaphragm and intercostal muscles. Over time, patients may experience shortness of breath and reduced lung capacity, particularly during exertion. Respiratory therapy and, in severe cases, mechanical ventilation support may be necessary.
Cardiac involvement can occur, manifesting as arrhythmias or cardiomyopathy. This is caused by the dystrophic process affecting cardiac muscle tissue. The progression of cardiac symptoms can lead to heart failure if not monitored and managed. Regular cardiac evaluations and appropriate medical interventions are crucial for managing this aspect of the disease.
What Causes Autosomal recessive limb-girdle muscular dystrophy, type 28?
Autosomal recessive limb-girdle muscular dystrophy type 28 is caused by mutations in the LAMA2 gene located on chromosome 6q22.33. The LAMA2 gene encodes the protein laminin alpha-2, which is a crucial component of the extracellular matrix in muscle tissue. Mutations in LAMA2 can lead to the production of a truncated or misfolded laminin alpha-2 protein, disrupting its ability to form stable interactions with other matrix components. This disruption compromises the structural integrity and signaling functions of the muscle cell basement membrane. As a result, muscle fibers experience increased mechanical stress and impaired repair mechanisms, leading to progressive muscle degeneration. The breakdown of muscle fibers can trigger an inflammatory response, exacerbating tissue damage. Neuroinflammation may also play a role, as immune cells infiltrate affected muscle tissues, further contributing to degeneration. Over time, the loss of muscle integrity can lead to secondary effects on peripheral nerves, potentially impacting white matter integrity. The pattern of muscle weakness, typically affecting the limb-girdle region, is due to the specific distribution of laminin alpha-2 in these muscles. Variability in disease severity among patients can be attributed to differences in mutation type, genetic background, and environmental factors. Some patients may experience more severe symptoms due to complete loss of laminin alpha-2 function, while others with partial function may have milder forms. Additionally, modifier genes and epigenetic factors can influence the clinical presentation. Understanding the precise molecular pathways affected by LAMA2 mutations is crucial for developing targeted therapies. Research continues to explore how these pathways can be modulated to slow disease progression.
How is Autosomal recessive limb-girdle muscular dystrophy, type 28 Diagnosed?
Typical age of diagnosis: Diagnosis typically occurs in late childhood to early adulthood, often prompted by the onset of muscle weakness and difficulty with activities requiring proximal muscle strength.
The clinician looks for signs of progressive muscle weakness, particularly in the shoulder and pelvic girdle areas. Family history is crucial, especially noting any consanguinity or similar symptoms in relatives. Physical examination may reveal muscle wasting, difficulty in rising from a seated position, and a waddling gait. This step helps differentiate limb-girdle muscular dystrophy from other neuromuscular disorders.
Magnetic Resonance Imaging (MRI) is commonly used to assess muscle integrity and detect patterns of muscle involvement. Specific abnormalities include fatty replacement and atrophy of the proximal muscles. These findings can confirm the diagnosis by correlating clinical symptoms with muscle changes. MRI also helps exclude other conditions like polymyositis or Becker muscular dystrophy.
Creatine kinase (CK) levels are typically elevated, indicating muscle damage. Additional blood tests may look for elevated transaminases and lactate dehydrogenase. Abnormal results show significantly increased CK levels, often several times the normal range. These results guide the clinician to pursue further genetic testing.
Genetic testing focuses on sequencing the SGCA, SGCB, SGCG, and SGCD genes, among others. Mutations such as nonsense, missense, or deletions are identified. The presence of pathogenic mutations confirms the diagnosis of autosomal recessive limb-girdle muscular dystrophy. Genetic results are crucial for family counseling and assessing carrier status in relatives.
Autosomal recessive limb-girdle muscular dystrophy, type 28 Treatment Options
Corticosteroids are used to slow muscle degeneration. They work by reducing inflammation and modulating immune response. Prednisone is commonly prescribed, with some evidence supporting its efficacy in preserving muscle strength. However, long-term use can lead to side effects such as osteoporosis, weight gain, and hypertension. Regular monitoring and dose adjustments are necessary to balance benefits and risks.
Physical therapy involves specific techniques like resistance training and stretching to maintain muscle function. The goal is to enhance mobility, prevent contractures, and improve quality of life. Sessions are typically conducted 2-3 times a week, lasting about an hour each. Measurable outcomes include improved range of motion and muscle strength. Long-term benefits include delayed progression of muscle weakness and enhanced daily functioning.
Surgery is indicated for severe contractures that limit mobility. The procedure involves releasing or lengthening tendons to improve joint function. Expected benefits include increased range of motion and reduced pain. Surgical risks include infection, bleeding, and potential nerve damage. Post-operative care requires physical therapy to maintain surgical gains and prevent recurrence.
The care team includes neurologists, physiotherapists, occupational therapists, and social workers. Interventions focus on optimizing physical function, providing adaptive equipment, and facilitating daily living activities. Psychosocial support strategies involve counseling and support groups for patients and families. Family education covers disease progression, management strategies, and genetic implications. Long-term monitoring involves regular assessments to adjust care plans as needed.
When to See a Doctor for Autosomal recessive limb-girdle muscular dystrophy, type 28
- Severe difficulty in breathing — this could indicate respiratory muscle involvement requiring immediate medical attention.
- Sudden cardiac symptoms like chest pain or palpitations — these may suggest cardiac involvement, which is a medical emergency.
- Acute muscle weakness leading to inability to walk — this could indicate rapid disease progression necessitating urgent evaluation.
- Progressive muscle weakness — this is a sign of disease progression and should be evaluated by a specialist.
- Frequent falls or balance issues — these indicate worsening muscle function and may require intervention.
- New onset of muscle pain or cramps — this could signify changes in disease status and should be discussed with a doctor.
- Mild fatigue after exertion — monitor energy levels and adjust activities as needed.
- Occasional muscle stiffness — keep track of frequency and manage with stretching exercises.
Autosomal recessive limb-girdle muscular dystrophy, type 28 — Frequently Asked Questions
Is this condition hereditary?
Autosomal recessive limb-girdle muscular dystrophy, type 28, is inherited in an autosomal recessive pattern. This means both copies of the gene in each cell have mutations. Parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene but typically do not show signs and symptoms of the condition. De novo mutations are not common in this condition. Genetic counseling is recommended for affected families to understand carrier status and reproductive options.
What is the life expectancy for someone with this condition?
Life expectancy can vary significantly depending on the age of onset and severity of symptoms. Early onset often correlates with a more severe progression and potentially shorter lifespan. Respiratory failure and cardiac complications are common causes of mortality. Timely interventions and supportive treatments can improve quality of life and potentially extend lifespan. Realistic expectations should include regular monitoring and proactive management of symptoms.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis typically involves a combination of clinical evaluation, family history, and genetic testing. The time from first symptoms to diagnosis can vary, often taking several months to years. Neurologists and geneticists are commonly consulted during the diagnostic process. Delays in diagnosis may occur due to symptom overlap with other muscular dystrophies. Genetic testing confirming mutations in the relevant gene is the definitive diagnostic step.
Are there any new treatments or clinical trials available?
Research is ongoing, with gene therapy and other novel approaches showing promise. ClinicalTrials.gov is a resource for finding relevant clinical trials. Patients should discuss potential trials and emerging treatments with their healthcare providers. While some treatments are in advanced stages of development, widespread availability may still be several years away. Realistic timelines should be discussed with specialists familiar with the condition.
How does this condition affect daily life and activities?
The condition significantly impacts mobility, often requiring assistive devices for walking. Educational adjustments may be necessary to accommodate physical limitations. Social and emotional challenges include coping with progressive disability and potential isolation. Family members may experience increased caregiving responsibilities. Supportive therapies and adaptive technologies can greatly enhance quality of life and independence.
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Limb girdle muscular dystrophy 2G in a religious minority of Bulgarian Muslims homozygous for the c.75G>A, p.Trp25X mutation.
Chamova T, Bichev S, Todorov T et al. · Neuromuscul Disord · 2018 · PMID: 29935994
- 2.Sarcoglycanopathies: a clinico-pathological study.
Meena AK, Sreenivas D, Sundaram C et al. · Neurol India · 2007 · PMID: 17558114
- 3.Dysferlinopathies: phenotypic study of a Moroccan series of 28 cases.
Mouloudi N, Kably B, Sefiani S et al. · Acta Myol · 2026 · PMID: 41954144
- 4.Dysferlinopathy in Tunisia: clinical spectrum, genetic background and prognostic profile.
Belhassen I, Laroussi S, Sakka S et al. · Neuromuscul Disord · 2023 · PMID: 37716854
- 5.LAMA2-related myopathy: Frequency among congenital and limb-girdle muscular dystrophies.
Løkken N, Born AP, Duno M et al. · Muscle Nerve · 2015 · PMID: 25663498
- 6.Cardiac dysrhythmias,cardiomyopathy and muscular dystrophy in patients with Emery-Dreifuss muscular dystrophy and limb-girdle muscular dystrophy type 1B.
Hong JS, Ki CS, Kim JW et al. · J Korean Med Sci · 2005 · PMID: 15832002
- 7.Characterization of novel CAPN3 isoforms in white blood cells: an alternative approach for limb-girdle muscular dystrophy 2A diagnosis.
Blázquez L, Azpitarte M, Sáenz A et al. · Neurogenetics · 2008 · PMID: 18563459
- 8.LGMD2E is the most common type of sarcoglycanopathies in the Iranian population.
Alavi A, Esmaeili S, Nilipour Y et al. · J Neurogenet · 2017 · PMID: 28687063
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-05-03